Details

Autor(en) / Beteiligte

• Chaiworapongsa, Tinnakorn, MD
• Romero, Roberto, MD
• Tarca, Adi L., PhD
• Kusanovic, Juan Pedro, MD
• Gotsch, Francesca, MD
• Mittal, Pooja, MD
• Kim, Sun Kwon, MD, PhD
• Vaisbuch, Edi, MD
• Mazaki-Tovi, Shali, MD
• Erez, Offer, MD
• Dong, Zhong, PhD
• Kim, Chong Jai, MD, PhD
• Yeo, Lami, MD
• Hassan, Sonia S., MD

Titel

A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia

Ist Teil von

• American journal of obstetrics and gynecology, 2010-06, Vol.202 (6), p.550.e1-550.e10

Ort / Verlag

New York, NY: Mosby, Inc

Erscheinungsjahr

2010

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Objective The aim of this study was to examine if maternal plasma concentrations of soluble vascular endothelial growth factor receptor (sVEGFR)-2 change prior to the diagnosis of preeclampsia. Study Design A longitudinal study was conducted in normal pregnant women (n = 160) and patients with preeclampsia (n = 40). Blood samples were collected at 7 gestational age intervals from 6 weeks to term. Plasma concentrations of sVEGFR-2 were determined by enzyme-linked immunosorbent assay. Analysis was performed with cross-sectional and longitudinal (mixed effects model) approaches. Results Mothers destined to develop preeclampsia have lower plasma sVEGFR-2 concentrations than those who will have a normal pregnancy (longitudinal approach; P < .05). Cross-sectional analysis suggested that the median plasma sVEGFR-2 concentration in women destined to develop preeclampsia was significantly lower than that in normal pregnant women from 28-31 weeks of gestation ( P = .001) or 6-10 weeks prior to the diagnosis ( P < .001). Conclusion A lower maternal plasma sVEGFR-2 concentration precedes the development of preeclampsia, both term and preterm.